VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Valneva SE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026
$5.51−0.10 (-1.78%)
Close on Oct 19, 2026
Valneva SE revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Commercialized products | – | – | – | €85.25M | €63.00M | €65.94M | – | – | – |
| Technologies and services | – | – | – | -€39.09M | €28.51M | €12.78M | – | – | – |
| COVID | – | – | – | €309.58M | €253.31M | €0 | – | – | – |
| Vaccine candidates | – | – | – | €5.57M | €3.26M | €31.60M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | YoY |
|---|---|---|---|---|---|---|---|---|
| Commercialized products | – | – | – | €19.57M | -€1.47M | -€8.47M | – | – |
| Technologies and services | – | – | – | -€50.88M | -€3.88M | €743.00K | – | – |
| COVID | – | – | – | -€42.84M | €3.93M | -€19.76M | – | – |
| Vaccine candidates | – | – | – | -€31.89M | -€55.03M | -€28.19M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Technologies and services | – | – | – | – | €28.51M | €12.78M | €7.04M | – | – |
| Commercialized products | – | – | – | – | €63.00M | €65.94M | €129.67M | – | – |
| Vaccine candidates | – | – | – | – | €3.26M | €31.60M | -€10.52M | – | – |
| IXIARO [member] | – | – | – | – | €45.10M | €48.50M | – | – | – |
| DUKORAL | – | – | – | €17.34M | €2.44M | €13.30M | – | – | – |
| Lyme VLA15 | – | – | – | -€45.87M | €14.27M | €31.60M | – | – | – |
| Services related to clinical trial material | – | – | – | €3.21M | €10.00M | €8.00M | – | – | – |
| IXIARO | – | – | – | €41.37M | €45.12M | €48.48M | – | – | – |
| Other services | – | – | – | €2.78M | €3.35M | €3.82M | – | – | – |
| Third party products | – | – | – | €26.55M | €15.44M | €4.16M | – | – | – |
| COVID [member] | – | – | – | – | €253.31M | – | – | – | – |
| COVID VLA2001 | – | – | – | €309.58M | €253.31M | – | – | – | – |
| Chikungunya VLA1553 | – | – | – | €5.57M | €3.26M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | €53.61M | €48.59M | €32.96M | -€23.80M | €54.79M | €68.36M | – | 30.7% | +10.3% |
| Canada [member] | €30.13M | €32.32M | €28.19M | €18.90M | €4.23M | €8.97M | €24.40M | 17.2% | -6.8% |
| Germany [member] | €17.47M | €18.37M | €13.50M | €68.53M | €966.00K | €7.26M | €10.50M | 10.0% | -4.9% |
| France | €14.67M | €7.22M | €5.87M | €46.61M | €1.37M | €1.62M | – | 8.4% | +103.2% |
| Nordics | €13.90M | €13.94M | €12.70M | €12.04M | €2.44M | €2.87M | €11.03M | 8.0% | -0.3% |
| Other Europe | €13.88M | €9.06M | €9.34M | €18.74M | €5.01M | €2.82M | -€5.28M | 7.9% | +53.2% |
| United Kingdom [member] | €12.64M | €19.49M | €20.27M | €181.13M | €256.08M | €2.89M | €8.61M | 7.2% | -35.1% |
| Austria [member] | €9.47M | €15.90M | €14.58M | €21.79M | €18.53M | €10.26M | €6.80M | 5.4% | -40.4% |
| Rest of World | €8.90M | €4.69M | €16.31M | €17.36M | €4.68M | €4.31M | – | 5.1% | +89.7% |
| Other markets [member] | – | – | – | – | €4.68M | €4.31M | €4.87M | – | – |
| United States [member] | – | – | – | – | €54.79M | €68.36M | €63.99M | – | – |
From the segment and revenue-disaggregation notes of Valneva's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.